Qwest downgraded at Raymond James: Qwest was downgraded from Market Perform to Underperform, Raymond James said. Valuation call, as the stock is already up 21% on the year. Takeover speculation is likely overdone. Charles Schwab coverage initiated at Prudential: Prudential said it is initiating coverage on SCHW with a Neutral Weight rating and $18 target price. Schering-Plough upgraded at Banc of America: SGP was upgraded to Neutral, Banc of America said. Stock is down 13% on the year, and the company could realize several catalysts over the next several quarters. Risks remain, however. $18 price target. Schering-Plough upgraded at Goldman: Goldman said it is upgrading SGP to Inline from Underperform. Raising estimates. Sunoco estimates raised at CSFB: CSFB said it is increasing its estimates on SUN for 2006 to $6.83 a share from $6.51 a share. Maintained Neutral rating. Target raised to $90 from $85 on its new model and valuation. Viropharma downgraded at Cowen: VPHM was downgraded to Underperform, SG Cowen said. Company will not win Vancocin case, and the stock could further fall down to $5-$6 a share. Viropharma downgraded at Piper: Piper said it is downgrading VPHM to a Market Perform rating due to concerns over generics.
Dow Jones estimates lowered at Morgan Stanley: Morgan Stanley said it is lowering its estimates on DJ for 2006 to $1.25 a share from $1.30 a share. Maintained Equalweight rating. Genentech estimates raised at Piper: Piper said it is raising its 2006 estimates on DNA by 8 cents to $1.85 a share after company raised its 2006 EPS goal. Maintained Outperform rating. Genentech outlook raised at Goldman: Goldman said it is increasing its estimates on DNA to $1.62 a share from $1.58 a share. Maintained Outperform rating. Genentech outlook raised at UBS: UBS said it is raising its 2006 EPS estimates on DNA by 6 cents to $1.86. Expects operating leverage to drive future growth. Maintained $110 target price. Gannett estimates lowered at Goldman: Goldman said it is lowering its estimates on GCI for the full year to $5.20 a share from $5.25. Maintained Overweight rating. HCA estimates cut at Goldman: Goldman said it is lowering its estimates on HCA for the full year to $3.15 a share from $3.24 a share. Tough flu comps and inline valuation keep it cool on hospital sector despite discount valuation to healthcare services. Intel estimates cut at Prudential: Prudential said it is cutting its 2006 estimates on Intel by 6 cents to 86 cents a share due to gross margin headwinds including share loss and potential inventory build. Maintained Underweight rating. Pride International estimates lowered at Morgan Stanley: Morgan Stanley said it is lowering its estimates no PDE for the full year to $2.13 a share from $2.40 a share citing trends in offshore rig construction.